Back to my company list

ATOM Accelerating Therapeutics for Opportunities in Medicine

The AI engine Fit Assessment

Beta

ATOM leverages machine learning and data-driven modeling to enhance drug discovery, focusing on developing new therapeutics and optimizing the drug design process.

Blurb

ATOM is a public-private partnership with the mission of transforming drug discovery by accelerating.

HQ Location

United States

Founded

2017

Employees

11 - 50

Total funding raised

Not available

Last Funding Event

Not available

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Discovery Optimization

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission accelerating the development of more effective therapies for patients. Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.